Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952916 | 0.93 | RBP4 (0.64) | RBP4 | |
| SCHEMBL17505260 | 0.93 | RBP4 (0.63) | RBP4 | |
| SCHEMBL29598307 | 0.93 | RBP4 (0.63) | RBP4 | |
| SCHEMBL20589480 | 0.92 | RBP4 (0.57) | RBP4 | |
| SCHEMBL29597931 | 0.92 | RBP4 (0.57) | RBP4 | |
| SCHEMBL17505280 | 0.91 | RBP4 (0.71) | RBP4 | |
| SCHEMBL29597989 | 0.91 | RBP4 (0.71) | RBP4 | |
| SCHEMBL20696200 | 0.89 | RBP4 (0.60) | RBP4 | |
| SCHEMBL17505282 | 0.89 | RBP4 (0.72) | RBP4 | |
| SCHEMBL29598015 | 0.89 | RBP4 (0.72) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-12364693-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | BELITE BIO, INC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-120129485-A | Methods, compositions, and systems for assessing visual function | 英属开曼群岛商倍亮生物有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119454705-A | Formulations and methods of use of RBP4 inhibitors | 倍亮生物有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250041227-A1 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | BELITE BIO INC (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4436577-A1 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio, Inc (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118574615-A | Tablet formulations of RBP4 inhibitors and methods of use | 倍亮生物有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | disclosed |
| US-11951100-B2 | Formulations of RBP4 inhibitors and methods of use | BELITE BIO, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3996714-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114364382-A | Formulations and methods of use of RBP4 inhibitors | 倍亮生物有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-11-25 | — | — | US | disclosed |
| US-11028098-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021007172-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | BELITE BIO, LLC (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20200197390-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | BELITE BIO, INC (KY) | 2020-06-25 | — | — | US | disclosed |
| US-20200197390-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | BELITE BIO, INC (KY) | 2020-06-25 | — | — | US | disclosed |
| WO-2020028723-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-02-06 | — | — | WO | disclosed |
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190031681-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | RBP4 2619/4885 |
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | PDE6C, SERPINA6, PDE6H | RBP4 11/4885 |
| US-12364693-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | RBP4, RBP1, FABP4 | RBP4 1/4885 |
| US-20200197390-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | RBP4, RBP1, FABP4 | RBP4 1/4885 |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | AGER, RBP4, RBP1 | RBP4 2/4885 |
| US-20210363155-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | RBP4 2807/4885 |
| US-20250041227-A1 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | RBP4, RBP1, RBM3 | RBP4 1/4885 |
| US-11028098-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | RBP4 2660/4885 |
| US-20190031681-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | RBP4 2660/4885 |
| US-11951100-B2 | Formulations of RBP4 inhibitors and methods of use | RBP4, RBP1, RBM3 | RBP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.